Octozi Raises $3M to Deploy Agentic AI in Clinical Trial Data Operations, Demonstrates Six-Fold Throughput Gains
核心洞察
Octozi (搜索) raised $3 million in seed funding led by Surface Ventures (搜索) to expand its agentic AI platform for clinical trial data operations.
In a controlled study, the platform increased data-cleaning throughput six-fold, reduced reviewer error rates from 54.7% to 8.5%, and cut false-positive queries fifteen-fold.
An economic analysis of a Phase III oncology trial estimated potential savings exceeding $5 million per study through faster database lock and compressed timelines.
Octozi (搜索), a New York City-based artificial intelligence company focused on automating clinical development workflows, has raised $3 million in seed funding to bring agentic AI into the data operations layer of pharmaceutical trials. Surface Ventures (搜索) led the round, with participation from Remarkable Ventures, building on a prior strategic investment from the venture arm of Swiss pharmaceutical company Debiopharm (搜索).
The capital will be used to expand Octozi (搜索)'s agentic AI platform and deepen its integrations with clinical systems used by pharmaceutical, biotech, and medtech companies.
Addressing a Decades-Old Bottleneck in Drug Development
Clinical trials generate vast volumes of data that must be cleaned, reconciled, and reviewed before regulators will approve new therapies. Much of this work is still performed manually by data managers, medical monitors, and safety teams, adding time, cost, and operational risk to drug development. Octozi (搜索)'s platform integrates with existing clinical systems and uses a human-in-the-loop design, keeping study teams in control while automating tasks such as data cleaning, data review, reconciliation, and reporting.
The technology combines large language models with deterministic clinical algorithms and external medical knowledge so that outputs reflect clinical context. For example, the system can distinguish an expected drop in platelet counts after chemotherapy from discrepant data that warrants investigation—a nuance that generic automation tools may miss.
"Most tools in this space put trial data on a dashboard and leave the analysis to clinical teams. Octozi (搜索) was built to perform that work alongside the people who own the data, with the human in control and the model handling tasks that previously took weeks of manual effort," said Amit Patel, Co-Founder and CEO of Octozi.
Quantifiable Impact on Trial Efficiency
The platform already supports Phase III trials, which are among the largest and most complex stages of clinical development and can involve thousands of patients. In a controlled study described in a published research paper, AI assistance from Octozi (搜索) increased data-cleaning throughput roughly six-fold, reduced reviewer error rates from approximately 54.7% to 8.5%, and lowered false-positive queries by roughly fifteen-fold.
An accompanying economic analysis of a representative Phase III oncology trial estimated potential savings of more than $5 million per study, primarily because databases could be locked sooner and timelines compressed.
Human-in-the-Loop Design Philosophy
Octozi (搜索) positions its platform as an operational layer designed around how clinical teams actually work, rather than as a dashboard that leaves interpretation to human reviewers. By embedding AI into existing workflows with human oversight, the company aims to reduce bottlenecks in data operations, improve the quality of submissions to regulators, and shorten the time it takes to move data through critical review steps.
"Clinical development is one of the most expensive and time-consuming processes in any industry, and the data operations layer underneath it has barely changed in decades. We think purpose-built AI, designed around how clinical teams actually work, can compress timelines, reduce risk, and bring down cost across the entire development cycle," Patel added.
Investors see the technology as a way to improve data quality, ease pressure on clinical and data teams, and potentially speed time to market for life-saving therapies. The platform's value proposition spans multiple dimensions: improving the quality of data submitted to regulatory bodies, helping clinical development and data teams become less of a bottleneck across all trials they manage, and accelerating specific tasks so that pharmaceutical companies can deliver data to regulators faster.